Patents by Inventor Paul M. Lieberman

Paul M. Lieberman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
    Patent number: 9309212
    Abstract: The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: April 12, 2016
    Assignee: The Wistar Institute
    Inventors: Paul M. Lieberman, Troy Messick
  • COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF EPSTEIN-BARR NUCLEAR ANTIGEN 1
    Publication number: 20140113897
    Abstract: The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.
    Type: Application
    Filed: May 22, 2012
    Publication date: April 24, 2014
    Applicant: THE WISTAR INSTITUTE
    Inventors: Paul M. Lieberman, Troy Messick